N
RUBY

Nuveen’s Rubius Therapeutics, Inc RUBY Stock Holding History

Nuveen’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-184,772
Closed -$1.02M – 3587
2022
Q1 		$1.02M Buy
184,772
+10,122
+6% +$64.3K ﹤0.01% 2814
2021
Q4 		$1.69M Buy
174,650
+29,924
+21% +$415K ﹤0.01% 2646
2021
Q3 		$3.02M Sell
144,726
-3,066
-2% -$66.7K ﹤0.01% 2479
2021
Q2 		$3.61M Sell
147,792
-11,701
-7% -$293K ﹤0.01% 2409
2021
Q1 		$4.23M Sell
159,493
-18,979
-11% -$277K ﹤0.01% 2242
2020
Q4 		$1.35M Sell
178,472
-745
-0.4% -$4.42K ﹤0.01% 2692
2020
Q3 		$897K Buy
179,217
+38,971
+28% +$206K ﹤0.01% 2731
2020
Q2 		$839K Sell
140,246
-55,955
-29% -$330K ﹤0.01% 2696
2020
Q1 		$873K Buy
196,201
+1,142
+0.6% +$8.48K ﹤0.01% 2568
2019
Q4 		$1.85M Buy
195,059
+62,721
+47% +$607K ﹤0.01% 2448
2019
Q3 		$1.04M Buy
132,338
+7,156
+6% +$83.4K ﹤0.01% 2693
2019
Q2 		$1.97M Buy
+125,182
New +$2.02M ﹤0.01% 2444

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's RUBY Position: Q2 2022 in Review

Nuveen sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 184,772 shares — an estimated $1.02M sold.

Nuveen first reported a position in RUBY in Q2 2019 and held it in 12 quarters. The position peaked at $4.23M in Q1 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Nuveen reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 184,772 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $1.02M.
  • Nuveen first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 12 quarters.
  • Nuveen's Rubius Therapeutics, Inc position peaked at $4.23M in Q1 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.